Remove Development Remove FDA Approval Remove Life Science
article thumbnail

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

While Symvess focuses on arterial repair, other developments like AQUACEL Ag+ Extra, Molnlycke Health Cares wound management technologies and Traumagel are advancing care in related areas. AQUACEL, currently undergoing clinical studies, aims to heal venous leg ulcers, while Molnlycke is improving chronic wound care.

article thumbnail

US FDA approves GSK’s Jesduvroq to treat anaemia of CKD

Pharmaceutical Technology

It is claimed to be the only HIF-PHI approved in the country that offers a new oral treatment option for adult patients on dialysis with anaemia of CKD. We are proud to have developed Jesduvroq as a new oral treatment where there is a patient desire for more options.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves First Fecal Matter Therapy + PureTech Reveals New CBD Oral Capsule – Xtalks Life Science Podcast Ep. 89

XTalks

In this episode, Ayesha talked about the FDA approval of Ferring Pharmaceuticals’ fecal matter-based therapy Rebyota for the treatment of recurrent C. Hear more about the drug and its approval in this episode. Read the full articles here: FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C.

article thumbnail

Interview with Polarean Imaging CTO Dr. Bastiaan Driehuys on the FDA Approval of Lung Imaging Drug Device Combo Xenoview – Xtalks Life Science Podcast Ep. 97

XTalks

Bastiaan Driehuys, PhD Founder and Chief Technology Officer Polarean Imaging plc In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Dr. Bastiaan Driehuys, Founder and Chief Technology Officer at Polarean Imaging plc. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Ctexli (Chenodiol) Gains FDA Approval as First CTX Treatment

XTalks

Mirum Pharmaceuticals, a biotech innovator known for developing therapies for rare metabolic disorders, now has FDA approval for its new treatment, Ctexli (chenodiol) tablets the first and only medication approved for cerebrotendinous xanthomatosis (CTX) in adults.

article thumbnail

Build Connections with B2B Audiences through the Xtalks Life Science Podcast

XTalks

Life science podcasts have emerged as an invaluable tool for building connections with audiences in the digital era. Furthermore, we’ll explore the unique advertising opportunities that this platform offers, positioning brands at the forefront of the life science industry. The result?

article thumbnail

Life Science Trends to Look Out for in 2024

XTalks

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.